安进Amgen Inc. (AMGN) 2001年年度报告「NASDAQ」.pdf

1、A LifeWorthLivingA m g e n2001 Annual ReportContents1Letter to Stockholders2Selected Financial Information6Financial Performance9Anemia13Cancer17Inflammation21R&D Targets24Products and Product Candidates25Managements Discussion and Analysisof Financial Condition and Results of Operations30Quantitati

2、ve and Qualitative Disclosures About Market Risk32Consolidated Financial Statements49Report of Ernst&Young LLP,Independent Auditors50Board of Directors and Executive Officers50Stockholder Informationultimate goalglobal leadership in thetreatment of anemia in all medical settings.Advancing that goal

3、further were theworldwide regulatory filings we submittedfor the use of Aranespin the treatment ofchemotherapy-induced anemia.Given therange of conditions that can induce anemia,and the growing body of evidence that its early identification and treatment mayenhance overall patient outcomes,webelieve

4、 the market for anemia treatmentswill approach$10 billion by 2005.Kineret(anakinra),the first therapeuticdelivered from our inflammation program,received U.S.approval in 2001 for use inthe treatment of the signs and symptoms of rheumatoid arthritis.Kineretis uniquein its ability to mitigate inflamma

5、tion byblocking interleukin-1,a key cytokineimplicated in the immune systems inflam-mation cascade.We believe the worldwidemarket for biologic treatments for rheuma-toid arthritis and related diseases willexceed$8 billion by 2005.1Kevin Sharer CHAIRMAN ANDCHIEFEXECUTIVEOFFICERLetter toStockholdersTh

6、e first year of the new century marked a transition point for Amgen in severalimportant ways.We launched two signifi-cant new products.We made promisingadvances in clinical and preclinical research.We brought new leadership into key areasof our business.We announced an acquisi-tion with great promis